Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Santhera Pharmaceuticals Holding AG

Santhera shares updates on commercial rollout of AGAMREE®
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera proposes Dr. Melanie Rolli as new member of Board of Directors
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Full Year Trading Update
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Announces Agreement with German GKV-SV on Reimbursement Amount for AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy in Germany
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Announces Chief Financial Officer Transition with Appointment of Catherine Isted
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Pharmaceuticals Provides Update on Royalty Agreement for AGAMREE® (Vamorolone) and Warrants held by Idorsia
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Receives Positive NICE Final Guidance for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy Patients in NHS Scotland
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Enters into Supply and Distribution Agreement for AGAMREE® (Vamorolone) with Clinigen Group
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Announces Approval in Hong Kong for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Announces Approval from China’s NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Receives Positive Recommendation from NICE for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Enters into Exclusive Supply Agreement for AGAMREE® (Vamorolone) with Ali Al Suwaidi Trading Establishment (ASTE) in Qatar
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Announces Positive Topline Results from LIONHEART Study with AGAMREE® (vamorolone) Demonstrating Unique Mineralocorticoid Receptor Antagonism
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Announces Acceptance by Swissmedic of Marketing Authorization Application for AGAMREE® (vamorolone) in Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Announces Half-Year 2024 Financial Results and Provides Corporate Update
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Enters into an Exclusive Distribution Agreement with GENESIS Pharma for AGAMREE® (Vamorolone) in Central and Eastern Europe
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Closes Financings and Secures Funds to Reach Break-Even Expected in 2026
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Appoints Dr. Oliver P. Kronenberg as Chief Legal Officer and Company Secretary
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Secures up to CHF 69 million in Royalty and Debt Financing to Fund Operations to Cash Flow Break-Even
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Announces Launch of Early Access Program in China for AGAMREE® by its Partner Sperogenix
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Publishes Agenda for its Annual General Meeting
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Publishes Annual Report 2023
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPA
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurology
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Santhera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy
From Santhera Pharmaceuticals Holding AG
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.